[go: up one dir, main page]

WO2006128012A3 - Appareil de secretion d'arginine translocase double : dosages de haut rendement et vecteurs de vaccin associes - Google Patents

Appareil de secretion d'arginine translocase double : dosages de haut rendement et vecteurs de vaccin associes Download PDF

Info

Publication number
WO2006128012A3
WO2006128012A3 PCT/US2006/020486 US2006020486W WO2006128012A3 WO 2006128012 A3 WO2006128012 A3 WO 2006128012A3 US 2006020486 W US2006020486 W US 2006020486W WO 2006128012 A3 WO2006128012 A3 WO 2006128012A3
Authority
WO
WIPO (PCT)
Prior art keywords
high throughput
throughput assays
twin arginine
vaccine vectors
secretory apparatus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020486
Other languages
English (en)
Other versions
WO2006128012A2 (fr
Inventor
Michael L Vasil
Adriana I Vasil
Urs A Ochsner
Aleksandra Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Publication of WO2006128012A2 publication Critical patent/WO2006128012A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006128012A3 publication Critical patent/WO2006128012A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des dosages de haut rendement permettant d'identifier les inhibiteurs spécifiques de l'appareil de sécrétion d'arginine translocase double. Cette invention concerne aussi des mutants d'arginine translocase double bactériens destinés à être utilisé comme vaccins, des vecteurs de vaccins ou des véhicules permettant d'apporter des agents thérapeutiques et, l'immunisation prophylactique et thérapeutique ainsi que des techniques de traitement utilisant ces vaccins, ces vecteurs et ces véhicules d'apport..
PCT/US2006/020486 2005-05-24 2006-05-24 Appareil de secretion d'arginine translocase double : dosages de haut rendement et vecteurs de vaccin associes Ceased WO2006128012A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68448905P 2005-05-24 2005-05-24
US60/684,489 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006128012A2 WO2006128012A2 (fr) 2006-11-30
WO2006128012A3 true WO2006128012A3 (fr) 2009-04-16

Family

ID=37452899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020486 Ceased WO2006128012A2 (fr) 2005-05-24 2006-05-24 Appareil de secretion d'arginine translocase double : dosages de haut rendement et vecteurs de vaccin associes

Country Status (1)

Country Link
WO (1) WO2006128012A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210353693A1 (en) * 2018-10-17 2021-11-18 SciBac Inc. Live Biotherapeutics to Treat and Prevent Lung Conditions
CN112237623B (zh) * 2020-10-30 2023-10-03 中国人民解放军陆军军医大学第二附属医院 铜绿假单胞菌III型分泌型蛋白PcrV及其诱导极化的巨噬细胞的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OCHNER. U.A. ET AL.: "Effects of the twi-arginine translocase on secretion of virulence factors, stress response, and pathogenesis.", PNAS, vol. 99, no. 12, 11 June 2002 (2002-06-11), pages 8312 - 8317 *
VOULHOUX, R. ET AL.: "Involvement of the twin-arginine translocation system in protein secretion via the type 11 pathway.", THE EMBO JOURNAL, vol. 20, no. 23, 2001, pages 6735 - 6741 *

Also Published As

Publication number Publication date
WO2006128012A2 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
EP4349868A3 (fr) Anticorps monoclonaux humanisés et chimériques contre cd47
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2006020773A3 (fr) Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes
WO2006138004A3 (fr) Compositions immunogenes pour chlamydia trachomatis
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
WO2009105513A8 (fr) Nouveaux composés et procédés pour la thérapie
WO2009117656A3 (fr) Antigène incorporé dans la capside pour nouveau vaccin à adénovirus
WO2006081007A3 (fr) Utilisation de flagelline en immunotherapie antitumorale
WO2006046978A3 (fr) Transformation par l'intermediaire de peptides cationiques
WO2008085962A3 (fr) Méthodes de culture cellulaire destinées à la production de protéines recombinées en présence de niveaux réduits d'un ou plusieurs contaminants
WO2007059008A3 (fr) Indenoisoquinolines n-substituees et leur synthese
WO2009114560A3 (fr) Compositions et procédés pour le diagnostic et le traitement d’une infection à cytomégalovirus
WO2008048344A3 (fr) Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
WO2013040478A3 (fr) Compositions dérivées de hyr1 et méthodes de traitement les utilisant
WO2008127094A3 (fr) Nouveaux facteurs de virulence de streptococcus pneumoniae
WO2008010098A3 (fr) Identification, optimisation et utilisation d'épitopes hla-b7 cryptiques pour une immunothérapie
WO2005017130A3 (fr) Lignees cellulaires tumorales et utilisations associees
WO2021005338A3 (fr) Nouveaux antigènes du cancer et procédés
MX2012004622A (es) Adyuvante para vacunas, vacunas que lo comprenden y usos.
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2006128012A3 (fr) Appareil de secretion d'arginine translocase double : dosages de haut rendement et vecteurs de vaccin associes
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
WO2004032599A3 (fr) Nouvelles proteines immunogenes de leptospira
WO2005089294A3 (fr) Synthese d'indenoisoquinoliniums et techniques d'utilisation
WO2004098529A3 (fr) Compositions therapeutiques et vaccins comprenant des cytokines a ancrage glycosyl-phosphatidylinositol (gpi) et des molecules immunostimulantes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06771321

Country of ref document: EP

Kind code of ref document: A2